Ionetix receives FDA approval for Gallium Ga-68 gozetotide ANDA
Ionetix Corporation announced FDA approval of its Abbreviated New Drug Application for Gallium Ga-68 gozetotide, a radioactive diagnostic agent for PSMA-PET imaging in prostate cancer patients. The approval expands the company's portfolio of positron emission tomography diagnostics and enables distribution through its multi-site network of PET facilities.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day